Delivery systems, compositions, and methods for forming and delivering biomaterials from two components are described. Specifically, a composition includes a first component and a second component that are each formulated to be crosslinked with the other to form a hydrogel. The first component and the second component are formulated to have an initial storage modulus (initial G) and an initial loss modulus (initial G″) when initially combined such that a ratio of the initial G″ to the initial G is between about 5 and about 100. The first component and the second component are formulated to have a gelation storage modulus (gelation G) and a gelation loss modulus (gelation G″) at a gelation time after the first component and the second component are combined such that a atio of the gelation G″ to the gelation G is less than about 1. The gelation time is less than about 120 seconds.

This document provides materials and methods for permanent arterial embolization and/or enhanced vascular healing. For example, materials and methods for using bioactive tissue derived nanocomposite hydrogels to enhance vascular healing are provided.

The present disclosure provides a method for creating a Biologically Modified Vein Graft with improved survival by pretreating the vein to be used as a vascular graft with compositions comprising oligo-L-arginine, or salts thereof, and an organic acid or a salt thereof. The disclosure further provides methods of improving vascular vein graft survival comprising pretreating the graft for a set period of time with a set concentration of oligo-L-arginines in a buffer comprising either the organic acid or the salt thereof and flushing the BMVG before implantation with the same buffer absent the arginine oligomer. This treatment may prevent vein graft disease in the transplanted vessel.

The present invention is a method and device for treating solid tumors utilizing shear thinning biomaterials compositions containing beta- or alpha emitting radiation sources, polymer matrix, and/or radiopaque agent. The novel radioactive composition which is disclosed here, can be injected percutaneously or via transcatheter vascular route into the target environment for the locoregional treatment. This invention is comprised of a shear thinning biomaterial which, when combined with a radioactive isotope source, can provide a therapeutic dose of radiation locally to the tumor site minimizing the risk of damage to surrounding tissue. The device may be used either as the primary tumor treatment or for treatment of residual cancer cells after excision of the primary tumor. The present invention provides a method for making the shear thinning radioactive biomaterial composition, as well as a method for utilizing the composition as a part of the treatment method.

Lung volume reduction by isolating a target lung portion from the rest of the lung with a mass of extracellular matrix (“ECM”) material. The procedure can be performed by locating a tube within the lumen of an airway to be obstructed and depositing an amount of flowable or other ECM in the open space until the lumen is occluded. Optionally, the procedure may be performed by delivering a plug substantially comprised of ECM material into the lumen of an airway to be obstructed. Further optionally, the ECM plug may include a one-way valve to allow air and mucous to escape from the isolated lung portion.

Polymeric particles are provided for use in therapeutic and/or diagnostic procedures. The particles include poly[bis(trifluoroethoxy)phosphazene and/or a derivative thereof which may be present throughout the particles or within an outer coating of the particles. The particles may also include a core having a hydrogel formed from an acrylic-based polymer. Such particles may be provided to a user in specific selected sizes to allow for selective embolization of certain sized blood vessels or localized treatment with an active component agent in specific clinical uses. Particles of the present invention may further be provided as color-coded microspheres or nanospheres to allow ready identification of the sized particles in use. Such color-coded microspheres or nanospheres may further be provided in like color-coded delivery or containment devices to enhance user identification and provide visual confirmation of the use of a specifically desired size of microspheres or nanospheres.

A method and kit for stopping cerebrospinal fluid (CSF) leaks, comprising penetrating and passing through a dural tissue an applicator to access an interior dural space, injecting from the applicator a fibrinogen-containing solution into said dural space, applying a sealing member containing a fibrinogen polymerizing agent onto an exterior surface of the dural tissue, and forming a polymerized fibrinogen or polymerized fibrin clot by contacting the injected fibrinogen-containing solution and the fibrinogen polymerizing agent.

An embolisation agent is a mixture of n-butyl cyanoacrylate and octyl cyanoacrylate having CPS ratios between 1-1000 cps. The invention is particularly related to a medical method and medical device used in treatments which enable to obturate, superficial varicosity, Pake and hemorrhoids with embolisation. By means of the device and method subject to the invention the progression of varicose veins, Pake and internal and external hemorrhoids can be stopped, obturated or clogged.

A polymer composition comprising a polymer and at least one active substance selected from the group consisting of a substance generating an occlusion, in particular a substance generating an internal occlusion or a substance generating an external occlusion; a moisturizing substance; a substance reducing pain or itching; and mixtures of these.

This disclosure relates to dermal treatment compositions, such as dermal fillers and tissue glues, and injectable compositions that incorporate one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the dermal treatment compositions to provide effective antimicrobial, anti-inflammatory, analgesic, anti-swelling and/or tissue-healing properties. A treatment composition includes a component formed from a biologically compatible material suitable for injection into and/or application onto tissue at a treatment site. One or more CSA compounds are mixed with the biologically compatible material so that the one or more CSA compounds are incorporated within the composition, forming a reservoir of CSA compounds within the resulting bolus of the treatment composition after injection and/or application.